MTNB — Matinas BioPharma Holdings Income Statement
0.000.00%
Last trade - 00:00- $3.10m
- -$4.16m
Annual income statement for Matinas BioPharma Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.158 | 0.033 | 3.19 | 1.1 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 23.3 | 23.4 | 24.3 | 24.4 | 24.6 |
| Operating Profit | -23.1 | -23.4 | -21.1 | -23.3 | -24.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22.4 | -23.3 | -21 | -22.9 | -24.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -22.4 | -23.3 | -21 | -22.9 | -24.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.4 | -23.3 | -21 | -22.9 | -24.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.2 | -23.7 | -21 | -22.9 | -24.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.17 | -5.95 | -5.65 | -5.39 | -4.39 |